{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:19:02Z","timestamp":1787764742684,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.surg.2026.110403","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:19:10Z","timestamp":1781885950000},"page":"110403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Reappraising the T category in hepatocellular carcinoma: Prognostic impact of the type and extent of vascular invasion"],"prefix":"10.1016","volume":"197","author":[{"given":"Shigeaki","family":"Kurihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0164-2414","authenticated-orcid":false,"given":"Hiroji","family":"Shinkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaaki","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeaki","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2026.110403_bib1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3350\/cmh.2020.0208","article-title":"Long-term prognosis and management of hepatocellular carcinoma after curative treatment","volume":"26","author":"Nishida","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.surg.2026.110403_bib2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1159\/000439101","article-title":"General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan","volume":"33","author":"Kudo","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.surg.2026.110403_bib3","first-page":"93","article-title":"AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.surg.2026.110403_bib4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.surg.2026.110403_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.hpb.2017.08.011","article-title":"Evaluation of hepatocellular carcinoma spread via the portal system by 3-dimensional mapping","volume":"19","author":"Fukutomi","year":"2017","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.surg.2026.110403_bib6","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.surg.2026.110403_bib7","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1002\/cncr.25960","article-title":"Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors","volume":"117","author":"Uchino","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.surg.2026.110403_bib8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2147\/CMAR.S147097","article-title":"Extrahepatic metastasis risk of hepatocellular carcinoma based on \u03b1-fetoprotein and tumor staging parameters at cross-sectional imaging","volume":"9","author":"Yokoo","year":"2017","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.surg.2026.110403_bib9","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1111\/ans.14708","article-title":"Nomogram predicting survival of hepatocellular carcinoma with portal vein tumour thrombus after curative resection","volume":"89","author":"Hu","year":"2019","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.surg.2026.110403_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/hepr.13297","article-title":"Liver resection versus transcatheter arterial chemoembolization for the treatment of patients with hepatocellular carcinoma and hepatic vein or inferior vena cava tumor thrombus: a propensity score matching analysis","volume":"49","author":"Chen","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.surg.2026.110403_bib11","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1245\/s10434-012-2739-y","article-title":"Microvascular Invasion does not predict long-term survival in hepatocellular carcinoma up to 2 cm: reappraisal of the staging system for solitary tumors","volume":"20","author":"Shindoh","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.surg.2026.110403_bib12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.29232","article-title":"Assessment of preoperative liver function based on indocyanine green clearance","volume":"66","author":"Kokudo","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.surg.2026.110403_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110403_bib14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jhep.2014.11.005","article-title":"Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion","volume":"62","author":"Pot\u00e9","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.surg.2026.110403_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/SLA.0b013e31825a01f6","article-title":"Use and dissemination of the Brisbane 2000 nomenclature of liver anatomy and resections","volume":"257","author":"Strasberg","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2026.110403_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.sla.0000197706.21803.a1","article-title":"Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications","volume":"243","author":"Portolani","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.surg.2026.110403_bib17","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.surg.2017.12.033","article-title":"Mortality and morbidity after hepatic resection in patients undergoing hemodialysis: analysis of a national inpatient database in Japan","volume":"163","author":"Shinkawa","year":"2018","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2026.110403_bib18","first-page":"80","article-title":"Impact of diabetes mellitus and obesity comorbidities on survival outcomes after hepatocellular carcinoma resection: a multicenter retrospective study","volume":"14","author":"Shinkawa","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.surg.2026.110403_bib19","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2014.04.032","article-title":"Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis","volume":"61","author":"Kokudo","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.surg.2026.110403_bib20","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.3748\/wjg.v28.i46.6433","article-title":"Recent progress in molecular mechanisms of postoperative recurrence and metastasis of hepatocellular carcinoma","volume":"28","author":"Niu","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.surg.2026.110403_bib21","first-page":"4367","article-title":"Usefulness of resection for hepatocellular carcinoma with macroscopic bile duct tumor thrombus","volume":"34","author":"Oba","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.surg.2026.110403_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3892\/ol.2020.11979","article-title":"Outcomes of resection for hepatocellular carcinoma with macroscopic bile duct tumour thrombus: a propensity score matched study","volume":"20","author":"Chi","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.surg.2026.110403_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.14701\/kjhbps.2015.19.4.167","article-title":"Bile duct invasion can be an independent prognostic factor in early stage hepatocellular carcinoma","volume":"19","author":"Jang","year":"2015","journal-title":"Korean J Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.surg.2026.110403_bib24","doi-asserted-by":"crossref","first-page":"20821","DOI":"10.1002\/cam4.6650","article-title":"Prognosis value of microscopic bile duct invasion in hepatocellular carcinoma: a multicenter study","volume":"12","author":"Huang","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.surg.2026.110403_bib25","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.surg.2026.110403_bib26","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.surg.2026.110403_bib27","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.annonc.2024.03.005","article-title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","volume":"35","author":"Melero","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.surg.2026.110403_bib28","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.surg.2026.110403_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","article-title":"Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma","volume":"21","author":"Llovet","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.surg.2026.110403_bib30","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","article-title":"Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"16","author":"Bruix","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2026.110403_bib31","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606026003284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606026003284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:30:55Z","timestamp":1787761855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606026003284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S0039606026003284"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2026.110403","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reappraising the T category in hepatocellular carcinoma: Prognostic impact of the type and extent of vascular invasion","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2026.110403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110403"}}